

Agneta Siegbahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9074862/publications.pdf>

Version: 2024-02-01

89
papers

7,610
citations

94433

37
h-index

56724

83
g-index

94
all docs

94
docs citations

94
times ranked

14803
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2022, 33, 425-431.	2.3	9
2	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	3.8	18
3	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation: Response to Luo and Bu. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 537-537.	3.8	0
4	Genetic Landscape of the ACE2 Coronavirus Receptor. <i>Circulation</i> , 2022, 145, 1398-1411.	1.6	20
5	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	2.7	6
6	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	8.4	70
7	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	2.7	7
8	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	3.8	17
9	A Multi-Cohort Metabolomics Analysis Discloses Sphingomyelin (32:1) Levels to be Inversely Related to Incident Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104476.	1.6	14
10	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020, 293, 35-41.	0.8	5
11	Role of Extracellular Vesicles in Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2293-2309.	2.4	21
12	Extracellular vesicles in atrial fibrillation and stroke. <i>Thrombosis Research</i> , 2020, 193, 180-189.	1.7	15
13	Activation of β_1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 519-534.	4.9	8
14	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	2.8	28
15	Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis. <i>Cancer Research</i> , 2020, 80, 3345-3358.	0.9	47
16	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 538-564.	3.4	64
17	Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner. <i>Uppsala Journal of Medical Sciences</i> , 2019, 124, 158-167.	0.9	6
18	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2402-2410.	2.4	25

#	ARTICLE	IF	CITATIONS
19	Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis. <i>Upsala Journal of Medical Sciences</i> , 2019, 124, 238-245.	0.9	1
20	Proteomic Biomarkers for Incident Aortic Stenosis Requiring Valvular Replacement. <i>Circulation</i> , 2018, 138, 590-599.	1.6	24
21	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
22	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1077-1087.	10.87	107
23	Sensitive and Specific Detection of Platelet-Derived and Tissue Factor-Positive Extracellular Vesicles in Plasma Using Solid-Phase Proximity Ligation Assay. <i>TH Open</i> , 2018, 02, e250-e260.	1.4	5
24	How to use D-dimer in acute cardiovascular care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 69-80.	1.0	60
25	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 500-510.	1.0	17
26	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
27	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	2.7	42
28	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	11.4	84
29	Impact of physical activity on cardiovascular status in obesity. <i>European Journal of Clinical Investigation</i> , 2017, 47, 167-175.	3.4	8
30	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	3.2	97
31	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1077-1087.	10.87	107
32	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1760-1776.	2.8	140
33	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	1.7	22
34	GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1576-1583.	1.8	60
35	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	2.8	95
36	Carotid Endarterectomy Induces the Release of Inflammatory Markers and the Activation of Coagulation as Measured in the Jugular Bulb. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2320-2328.	1.6	3

#	ARTICLE	IF	CITATIONS
37	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. <i>Upsala Journal of Medical Sciences</i> , 2017, 122, 224-233.	0.9	15
38	A stromal cell population in the large intestine identified by tissue factor expression that is lost during colorectal cancer progression. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1050-1059.	3.4	3
39	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
40	Cross-talk between the Tissue Factor/coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer. <i>BMC Cancer</i> , 2016, 16, 341.	2.6	9
41	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016, 387, 2302-2311.	13.7	389
42	Circulating cell-derived microparticles as biomarkers in cardiovascular disease. <i>Biomarkers in Medicine</i> , 2016, 10, 1009-1022.	1.4	26
43	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	1.3	21
44	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
45	The ABC risk score for patients with atrial fibrillation – Authors' reply. <i>Lancet, The</i> , 2016, 388, 1980-1981.	13.7	3
46	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. <i>JAMA Cardiology</i> , 2016, 1, 451.	6.1	137
47	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44
48	The composition and daily variation of microparticles in whole blood in stable coronary artery disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 25-32.	1.2	14
49	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	2.9	34
50	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1447-1456.	2.9	41
51	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517.	2.9	67
52	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.2	329
53	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016, 37, 1325-1333.	2.2	137
54	Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 691-699.	2.7	24

#	ARTICLE	IF	CITATIONS
55	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. <i>European Heart Journal</i> , 2015, 36, 1901-1912.	2.2	107
56	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	3.2	37
57	Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. <i>Atherosclerosis</i> , 2015, 242, 205-210.	0.8	108
58	High Plasma Levels of Heparin-Binding Epidermal Growth Factor Are Associated With a More Stable Plaque Phenotype and Reduced Incidence of Coronary Events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 222-228.	2.4	15
59	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. <i>American Heart Journal</i> , 2015, 169, 879-889.e7.	2.7	42
60	Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets. <i>Diabetologia</i> , 2015, 58, 2563-2572.	6.3	11
61	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 1151-1160.	2.7	99
62	Associations between circulating proteins and corresponding genes expressed in coronary thrombi in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2015, 136, 1240-1244.	1.7	6
63	Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. <i>Stroke</i> , 2015, 46, 3340-3347.	2.0	71
64	Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor. <i>Thrombosis and Haemostasis</i> , 2014, 111, 748-760.	3.4	13
65	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial." <i>Journal of the American College of Cardiology</i> , 2014, 63, 1081-1082.	0.784314	10
66	Large-scale Metabolomic Profiling Identifies Novel Biomarkers for Incident Coronary Heart Disease. <i>PLoS Genetics</i> , 2014, 10, e1004801.	3.5	225
67	The Eph Tyrosine Kinase Receptors EphB2 and EphA2 Are Novel Proteolytic Substrates of Tissue Factor/Coagulation Factor VIIa. <i>Journal of Biological Chemistry</i> , 2014, 289, 32379-32391.	3.4	18
68	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.	2.8	133
69	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1847-1858.	1.6	243
70	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	2.9	47
71	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATElet inhibition and patient Outcomes study. <i>American Heart Journal</i> , 2014, 168, 96-102.e2.	2.7	17
72	Discovery and refinement of loci associated with lipid levels. <i>Nature Genetics</i> , 2013, 45, 1274-1283.	21.4	2,641

#	ARTICLE	IF	CITATIONS
73	GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men. PLoS ONE, 2013, 8, e78797.	2.5	108
74	ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing. PLoS ONE, 2011, 6, e25583.	2.5	80
75	Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thrombosis and Haemostasis, 2005, 93, 27-34.	3.4	37
76	Role of Platelet P-Selectin and CD40 Ligand in the Induction of Monocytic Tissue Factor Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2322-2328.	2.4	217
77	Induction of differentiation in U937 and NB4 cells is associated with inhibition of tissue factor production. European Journal of Haematology, 1999, 63, 112-119.	2.2	9
78	Cell Interactions with Collagen Matrices <i>In Vivo</i> and <i>In Vitro</i> Depend on Phosphatidylinositol 3-Kinase and Free Cytoplasmic Calcium. Cell Adhesion and Communication, 1998, 5, 461-473.	1.7	32
79	Plasminogen Activator Inhibitor-1 Activity Is Independently Related to Both Insulin Sensitivity and Serum Triglycerides in 70-Year-Old Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 258-264.	2.4	94
80	Venous thrombosis: factor V G1691A genotyping related to APC resistance as measured by 2 methods. European Journal of Haematology, 1997, 58, 229-232.	2.2	5
81	Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines. British Journal of Haematology, 1996, 95, 249-257.	2.5	49
82	Thrombin Generation During Cardiopulmonary Bypass Using Heparin-Coated or Standard Circuits. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1995, 29, 157-165.	0.2	16
83	Pdgf-BB Triggered Cytoplasmic Calcium Responses in Cells with Endogenous or Stably Transfected PDGF β -Receptors. Growth Factors, 1995, 12, 191-201.	1.7	19
84	A Unique Autophosphorylation Site in the Platelet-Derived Growth Factor alpha Receptor from a Heterodimeric Receptor Complex. FEBS Journal, 1994, 225, 29-41.	0.2	47
85	Platelet-Derived Growth Factor is Angiogenic <i>In Vivo</i> . Growth Factors, 1992, 7, 261-266.	1.7	258
86	Specific binding of B-CLL cell-derived chemokinetic inhibitory factor (CIF) to human polymorphonuclear leukocytes. European Journal of Haematology, 1987, 39, 172-179.	2.2	4
87	The chemokinetic inhibitory factor (CIF) in serum of CLL patients: Correlation with infection propensity and disease activity. Scandinavian Journal of Haematology, 1985, 35, 80-87.	0.0	9
88	Cellular Origin of the Chemokinetic Inhibitor of Polymorphonuclear Leucocytes Found in Sera from Patients with Chronic Lymphocytic Leukaemia. Scandinavian Journal of Haematology, 1983, 31, 184-192.	0.0	6
89	Identification of a Chemokinetic Inhibitor in Serum from Patients with Chronic Lymphocytic Leukaemia. Scandinavian Journal of Haematology, 1982, 28, 122-131.	0.0	12